Yissum Ltd. Spins Off Start-Up Nanolymf to Advance Breakthrough Liver-Bypassing Oral Drug Delivery Technology

JERUSALEM--(BUSINESS WIRE)--Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs. Nanolymf was founded as a subsidiary of Shizim Ltd., a leading group of life science companies in Israel. Nanolymf's technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy and is exclusively licensed from Yissum. Per the terms of the agreement, Nanolymf has acquired exclusive rights and Yissum will receive royalties, sublicense fees, and an equity stake in Nanolymf.